Q2041 Axicabtagene ciloleucel car+
Q-Codes
Also known as: Yescarta, axicabtagene ciloleucel, CAR-T
Axicabtagene ciloleucel CAR+ therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive B-cell malignancies.
Clinical Context
Used for relapsed/refractory large B-cell lymphomas and multiple myeloma. Engineered T-cells target CD19+ cancer cells. Requires hospitalization for infusion and monitoring.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.